RBC Capital Maintains Outperform on Amgen, Raises Price Target to $430
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice TargetHot
RBC Capital analyst Luca Issi maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $400 to $430.
RBC Capital analyst Luca Issi maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $400 to $430.